Last reviewed · How we verify

Sitagliptin (Januvia) — Competitive Intelligence Brief

Sitagliptin (Januvia) (Sitagliptin (Januvia)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor. Area: Diabetes.

marketed DPP-4 inhibitor DPP-4 (dipeptidyl peptidase-4) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Sitagliptin (Januvia) (Sitagliptin (Januvia)) — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4), an enzyme that breaks down incretin hormones, thereby increasing insulin secretion and reducing glucagon in response to meals.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Sitagliptin (Januvia) TARGET Sitagliptin (Januvia) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) marketed DPP-4 inhibitor DPP-4 (dipeptidyl peptidase-4)
Linagliptin / Metformin Oral Tablet Linagliptin / Metformin Oral Tablet Universidad de Guanajuato marketed DPP-4 inhibitor / Biguanide combination DPP-4 (dipeptidyl peptidase-4) / AMPK pathway
sitagliptin and acarbose sitagliptin and acarbose Nanjing First Hospital, Nanjing Medical University marketed DPP-4 inhibitor + alpha-glucosidase inhibitor combination DPP-4 enzyme; alpha-glucosidase enzymes
Metformin / alogliptin Oral Product Metformin / alogliptin Oral Product University of Catanzaro marketed Biguanide / DPP-4 inhibitor combination Metformin: mitochondrial glycerophosphate dehydrogenase; Alogliptin: dipeptidyl peptidase-4 (DPP-4)
alogliptin + pioglitazone alogliptin + pioglitazone Kun-Ho Yoon marketed DPP-4 inhibitor + thiazolidinedione DPP-4 and PPAR-γ
Galvus (vildagliptin) Galvus (vildagliptin) Korea University Anam Hospital marketed DPP-4 inhibitor DPP-4 (dipeptidyl peptidase-4)
Metformin and Saxagliptin Metformin and Saxagliptin ikfe-CRO GmbH marketed Biguanide + DPP-4 inhibitor combination Metformin: mitochondrial glycerophosphate dehydrogenase; Saxagliptin: DPP-4 (dipeptidyl peptidase-4)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor class)

  1. Merck Sharp & Dohme LLC · 5 drugs in this class
  2. Daewoong Pharmaceutical Co. LTD. · 4 drugs in this class
  3. AstraZeneca · 4 drugs in this class
  4. LG Life Sciences · 2 drugs in this class
  5. Tanabe Pharma Corporation · 2 drugs in this class
  6. Ain Shams University · 2 drugs in this class
  7. Ono Pharmaceutical Co. Ltd · 2 drugs in this class
  8. Cinnagen · 1 drug in this class
  9. GRADE Study Group · 1 drug in this class
  10. CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sitagliptin (Januvia) — Competitive Intelligence Brief. https://druglandscape.com/ci/sitagliptin-januvia. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: